
News|Articles|April 1, 2003
Avandia (rosiglitazone)
This drug from the thiazolidinedione class is now approved for use incombination therapy with insulin, expanding on the existing indicationsas monotherapy and as combination therapy with metformin or sulfonylureas.Rosiglitazone improves sensitivity to insulin in muscle and adipose tissueand inhibits hepatic gluconeogenesis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
7 takeaways from the MHE webinar on PBM reform and transparency
3
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
4
What employees may miss when they buy drugs directly online
5





















